Recent Posts
- Blocking Cancer-Promoting Protein: Enzyme Inhibitor Takes An Unexpected Approach
- Prevent Periodontitis To Reduce The Risk Of Head And Neck Cancer
- Over Ninety Per Cent Of Pathologists Find Research Rules Too Complex
- New Progenitor Cell in Mice Can Cause Prostate Cancer
- Aggressive Prostate Cancer Linked to Trichomonas (CME/CE)
Random Posts
- Moving Images Reveal Secrets Behind Breast Cancer Spread
- Brain Tumor Incidence Unchanged During A Time When Cell Phone Usage Increased
- FISH Technology Preferred For Choosing HER-2-Positive Breast Cancer Treatments
- Shorter Hospital Stays but More ED with Robotic Prostatectomy (CME/CE, with video)
- ASTRO: Hormones Plus Radiation Ups Survival in Prostate Cancer (CME/CE)
- SABCS: Confirmation of Chemo Benefit in Breast Cancer (CME/CE)
- House Bill To Provide Cancer Patients With Solution For Quality Cancer Care Within An Equitable Medicare Model
- License From Saladax Biomedical Is Foundation Of New Molecular Oncology Test Launched By Myriad Genetics
- Cancer May Be Stopped In Its Tracks By MicroRNA Replacement Therapy
- Texas State Tests Potential New Cancer-Fighting Weapon
Prescription Cancer Drugs
Toward New Drugs That Turn Genes On And Off
Posted by: admin in Prescription Cancer Drugs on June 10th, 2009
Scientists in Michigan and California are reporting an advance toward development of a new generation of drugs that treat disease by orchestrating how genes in the body produce proteins involved in arthritis, cancer and a range of other disorders. Acting like an “on-off switch,” the medications might ratchet up the production of proteins in genes working at abnormally low levels or shut off genes producing an abnormal protein linked to disease. Their report is in the current issue of ACS Chemical Biology, a monthly journal.
In the study, Anna K. Mapp and colleagues discusses molecules that cause genes to be active and churn out proteins - so-called transcriptional activators. That’s because they control a key process known as transcription, in which instructions coded in genes produce proteins. Malfunctions in these activators could lead to altered transcription patterns that lead to disease. For example, variations in the tumor suppressor gene p53 are found in more than half of all human cancers.
Mapp describes discovery of a group of molecules that could be used to help scientists better understand transcription. Known as activator artificial transcriptional activation domains, these small molecules mimic natural activators and could provide insights on how mistakes in gene regulation result in various diseases. “Evidence suggests that these small molecules mimic the function and mechanism of their natural counterparts and present a framework for the broader development of small molecule transcriptional switches,” Mapp states.
Article:
“Amphipathic Small Molecules Mimic the Binding Mode and Function of Endogenous Transcription Factors”
http://pubs.acs.org/stoken/presspac/presspac/full/10.1021/cb900028j
Contact:
Anna K. Mapp, Ph.D.
University of Michigan
Ann Arbor, Mich.
Source:
Michael Woods
American Chemical Society
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.